

**Title: Humoral waning kinetics against SARS-CoV-2 is dictated by disease severity and vaccine platform**

**Authors:** Xin Tong,<sup>1†</sup> Benjamin Kellman,<sup>1†</sup> Maria-Jose Avendano,<sup>2,†</sup> Maanasa Mendu,<sup>1</sup> Jeff C. Hsiao,<sup>1,8</sup> Eileen Serrano,<sup>2</sup> Tamara Garcia-Salum,<sup>2,3,4</sup> Nicolas Muena,<sup>5</sup> Catalina Pardo-Roa,<sup>2,4,6</sup> Mauricio Morales,<sup>3</sup> Jorge Levican,<sup>2</sup> Erick Salinas,<sup>2</sup> Simone Cardenas-Cáceres,<sup>5</sup> Arnoldo Riquelme,<sup>7</sup> Nicole D. Tischler,<sup>5,8</sup> Douglas A. Lauffenburger,<sup>9</sup> Galit Alter,<sup>1</sup> Ryan P. McNamara,<sup>1</sup> Rafael A. Medina,<sup>2,3,4,10</sup>

**Affiliations:**

<sup>1</sup> Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, 02139, USA

<sup>2</sup> Department of Pathology and Laboratory Medicine, School of Medicine, Emory University, Atlanta, GA 30322, USA

<sup>3</sup> Department of Pediatric Infectious Diseases and Immunology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago 8331010, Chile

<sup>4</sup> Advanced Interdisciplinary Rehabilitation Register (AIRR) - COVID-19 Working Group, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago 8331010, Chile

<sup>5</sup> Laboratorio de Virología Molecular, Fundación Ciencia and Vida, Santiago 8581151, Chile

<sup>6</sup> Department of Child and Adolescent Health, School of Nursing, Pontificia Universidad Católica de Chile, Santiago 8331010, Chile

<sup>7</sup> Department of Gastroenterology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago 8331010, Chile

<sup>8</sup> Escuela de Bioquímica, Facultad de Salud y Ciencia, Universidad San Sebastián, Santiago 7510156, Chile.

<sup>9</sup> Department of Biological Engineering, Massachusetts Institute of Technology, Massachusetts, MA, 02139, USA

<sup>10</sup>Center for Research on Influenza Pathogenesis and Transmission (CRIPT) Center of Excellence of Influenza Research and Response (CEIRR), New York, New York, USA

† These authors contributed equally

\*Corresponding authors: Ryan McNamara (RPMCNAMARA@mgh.harvard.edu), Rafael A. Medina (rafael.medina@emory.edu)

## **Supplementary Material**

Contains Tables S1-S2

Contains Figs S1-S8 and corresponding figure captions

**Supplementary Table S1. Demographic and baseline characteristics of the cohort.**

	Outpatients (a) (n = 41)	Hospitalized (b) (n = 36)	CoronaVa c (c) (n = 34)	BNT162b2 (d) (n = 15)	P value*	P value#	Outpatients CoronaVac (n = 26)	Hospitalized CoronaVac (n = 16)	P value^	Outpatients BNT162b2 (n = 3)	Hospitalized BNT162b2 (n = 2)	P value^
<b>Characteristics</b>												
Male, n (%)	21 (51.2)	25 (69.4)	10 (29.4)	3 (20.0)	<b>0.0010</b>	<b>0.010 (b,c)</b> <b>0.011 (b,d)</b>	11 (42.3)	10 (62.5)	0.3408	1 (33.3)	1 (50)	1
Age, median (IQR)	32 (40-26)	53.5 (62.5-37.0)	33 (44-27.25)	36 (38.5-24.5)	< <b>0.0001</b>	<b>0.0002 (a,b)</b> <b>0.0009 (b,c)</b> <b>0.0040 (b,d)</b>	33 (54.75-27.75)	53.5 (62.5-37)	<b>0.0295</b>	27 (28.5-20)	55 (58.5-51-5)	0.1489
> 60 years, n (%)	4 (9.8)	12 (33.3)	1 (2.9)	0 (0)	<b>0.0007</b>	<b>0.0083 (b,c)</b>	3 (11.5)	5 (31.3)	0.2233	0 (0)	1 (50)	0.4
<b>Comorbidities or conditions</b>												
Obesity (BMI ≥ 30), n (%)	5 (12.2)	13 (36.1)	5 (14.7)	3 (20)	0.0613	NS	2 (7.7)	7 (43.8)	<b>0.0161</b>	1 (33.3)	1 (50)	1
Hypertension, n (%)	3 (7.3)	12 (33.3)	3 (8.8)	2 (13.3)	<b>0.0119</b>	<b>0.047 (a,b)</b>	3 (11.5)	6 (37,5)	0.0628	0 (0)	0 (0)	NA
Cardiovascular disease, n (%)	0 (0)	3 (8.3)	0 (0)	0 (0)	0.0774	NS	0 (0)	1 (6.3)	0.3810	0 (0)	0 (0)	NA
Chronic pulmonary disease, n (%)	6 (14.6)	3 (8.3)	0 (0)	0 (0)	0.0623	NS	4 (15.4)	1 (6.3)	0.6332	1 (33.3)	0 (0)	1
Asthma, n (%)	8 (19.5)	2 (5.6)	4 (11.8)	4 (26.7)	0.1310	NS	6 (23.1)	0 (0)	0.0671	1 (33.3)	0 (0)	1
Rheumatologic disease, n (%)	0 (0)	2 (5.6)	0 (0)	1 (6.7)	0.1327	NS	0 (0)	1 (6.3)	0.3810	0 (0)	0 (0)	NA
Immunocompromise, n (%)	0 (0)	5 (13.9)	0 (0)	0 (0)	<b>0.0069</b>	NS	0 (0)	3 (18.8)	0.0488	0 (0)	0 (0)	NA
Allergy <sup>+</sup> , n (%)	20 (48.8)	6 (16.7)	17 (50)	6 (40)	<b>0.0089</b>	<b>0.023 (a,b)</b> <b>0.028 (b,c)</b>	12 (46.2)	2 (12.5)	<b>0.0420</b>	3 (100)	0 (0)	0.1
Neurologic disease, n (%)	0 (0)	4 (11.1)	0 (0)	0 (0)	<b>0.0217</b>	NS	0 (0)	2 (12.5)	0.1394	0 (0)	0 (0)	NA
Smoker, n (%)	6 (14.6)	9 (25.0)	5 (14.7)	4 (26.7)	0.4962	NS	4 (15.4)	4 (25)	0.4538	1 (33.3)	0 (0)	1
<b>Previous treatment</b>												
Immunosuppressive drugs, n (%)	0 (0)	5 (13.9)	0 (0)	0 (0)	<b>0.0071</b>	NS	0 (0)	3 (18.8)	<b>0.0488</b>	0 (0)	0 (0)	NA
<b>Symptoms</b>												
<b>Respiratory</b>												
Cough, n (%)	28 (68.3)	30 (83.3)	NA	NA	0.1855		19 (73.1)	13 (81.3)	0.7152	3 (100)	2 (100)	NA
Dyspnea, n (%)	7 (17.1)	19 (52.8)	NA	NA	<b>0.0015</b>		6 (23.1)	11 (68.8)	<b>0.0084</b>	1 (33.3)	2 (100)	0.4
Odynophagia, n (%)	21 (51.2)	6 (16.7)	NA	NA	<b>0.0019</b>		15 (57.7)	2 (12.5)	<b>0.0045</b>	1 (33.3)	0 (0)	1
<b>Constitutional</b>												
Fever, n (%)	22 (53.7)	30 (83.3)	NA	NA	<b>0.0073</b>		14 (53.8)	14 (87.5)	<b>0.0420</b>	1 (33.3)	2 (100)	0.4
Headache, n (%)	34 (82.9)	13 (36.1)	NA	NA	< <b>0.0001</b>		23 (88.5)	5 (31.3)	<b>0.0004</b>	2 (66.7)	2 (100)	1
Myalgia, n (%)	26 (63.4)	17 (47.2)	NA	NA	0.1742		16 (61.5)	9 (56.3)	0.7570	3 (100)	0 (0)	0.1
Severe fatigue, n (%)	0 (0)	21 (58.3)	NA	NA	< <b>0.0001</b>		0 (0)	11 (68.8)	< <b>0.0001</b>	0 (0)	1 (50)	0.4
Altered mental status, n (%)	0 (0)	3 (8.3)	NA	NA	0.0976		0 (0)	1 (6.3)	0.3810	0 (0)	0 (0)	NA

Abbreviations: IQR, interquartile range; NA, not applicable; NS, not statistically significant.

<sup>+</sup> Allergy considered self-reported allergic rhinitis (by seasonal, perennial/year-round, or episodic allergens) and food allergy.

Categorical variables compared using Fisher-Freeman-Halton's exact test<sup>\*</sup>; Pairwise Fisher's exact test<sup>#</sup>; Fisher's exact test<sup>^</sup>.


Continuous variables compared using Kruskal-Wallis test<sup>\*</sup>; Wilcoxon Rank Sum<sup>#</sup>.

**Supplementary Table 2. List of reagents and resources used in this study.**


<b>REAGENT or RESOURCE</b>	<b>SOURCE</b>	<b>IDENTIFIER</b>
<b>Anti-Human IgG1-PE</b>	Southern Biotech	HP6001
<b>Anti-human IgG2-PE</b>	Southern Biotech	31-7-4
<b>Anti-human IgG3-PE</b>	Southern Biotech	HP6050
<b>Anti-human IgG4-PE</b>	Southern Biotech	HP6025
<b>Anti-human IgM-PE</b>	Southern Biotech	SA-DA4
<b>Anti-human IgA1-PE</b>	Southern Biotech	HP6025
<b>Human FcγRIIA</b>	Duke Human Vaccine Institute	Custom Order
<b>Human FcγRIIB</b>	Duke Human Vaccine Institute	Custom Order
<b>Human FcγRIIAV</b>	Duke Human Vaccine Institute	Custom Order
<b>Human FcγRIIB</b>	Duke Human Vaccine Institute	Custom Order
<b>Anti-CD66b Pac Blue</b>	BioLegend	305112
<b>SARS-CoV-2 WT S1</b>	Sino Biological	40591-V08H
<b>SARS-CoV-2 WT S2</b>	Sino Biological	40590-V08B
<b>SARS-CoV-2 WT Spike</b>	Sino Biological	40589-V08H4
<b>SARS-CoV-2 WT NTD</b>	Sino Biological	40591-V49H
<b>SARS-CoV-2 WT Receptor Binding Domain (RBD)</b>	Sino Biological	40592-V08H
<b>SARS-CoV-2 Alpha Variant S</b>	Sino Biological	40589-V08B6
<b>SARS-CoV-2 Alpha Variant RBD</b>	Sino Biological	40592-V08H82
<b>SARS-CoV-2 Beta Variant S</b>	Sino Biological	40589-V08B7
<b>SARS-CoV-2 Beta Variant RBD</b>	Sino Biological	40592-V08H59
<b>SARS-CoV-2 Gamma Variant S</b>	Sino Biological	40589-V08B10
<b>SARS-CoV-2 Gamma Variant RBD</b>	Sino Biological	40592-V08H86
<b>SARS-CoV-2 Delta Variant S</b>	Sino Biological	40589-V08B16
<b>SARS-CoV-2 Delta Variant RBD</b>	Sino Biological	40592-V08H115
<b>SARS-CoV-2 Omicron Variant S</b>	Sino Biological	40589-V08H26
<b>SARS-CoV-2 Nucleocapsid</b>	Sino Biological	40588-V08B
<b>SARS-CoV-2 Omicron Variant RBD</b>	Sino Biological	40592-V08H121
<b>Human Coronavirus OC43 S</b>	Sino Biological	40607-V08B
<b>Human CoV HKU1 S (isolate N5)</b>	Sino Biological	40606-V08B
<b>PE-Streptavidin</b>	Agilent Technologies	PB32-10
<b>NHS-Sulfo-LC-LC Kit</b>	ThermoFisher	21435
<b>Zebra-Spin Desalting and Chromatography Columns</b>	ThermoFisher	89882
<b>Green Fluorescent Neutravidin Microspheres</b>	ThermoFisher	F8776
<b>Red Fluorescent Neutravidin Microspheres</b>	ThermoFisher	F8775

<b>MagPlex Microspheres</b>	Luminex MFG	MC12001-01 (Cataloged by region)
<b>THP-1 Monocytes</b>	ATCC	CVCL_0006
<b>384-well HydroSpeed Plate Washer</b>	Tecan	30190112
<b>iQue Screener Plus</b>	Intellicyt/Sartorius	11811
<b>iQue Forecyt</b>	Sartorius	60028
<b>Vero E6 cells</b>	ATCC	CRL-1586, RRID: CVCL_0574
<b>MEM</b>	Gibco	11095-080
<b>FBS</b>	Gibco	16000-044
<b>pCEP4-myc-ACE2</b>	Addgene	141185
<b>Hygromycin</b>	Invitrogen	10687010
<b>Optical bottom 96-well plates</b>	Thermo Scientific	165305
<b>Formaldehyde</b>	Pierce	28906
<b>4',6-diamidino-2-phenylindole (DAPI)</b>	Invitrogen	D1306
<b>R Studio V 1.4.1103</b>	RStudio, PBC	Open Source
<b>GraphPad Prism</b>	GraphPad Software, LLC	Ragon Site License
<b>FlowJo V. 10.8</b>	FlowJo, LLC	<a href="http://www.flowjo.com/solutions/flowjo/downloads">www.flowjo.com/solutions/flowjo/downloads</a>


**A**






**B**



**C**






**Supplemental FigS1. WT Spike subdomain-specific MFI decay over time post-infection or vaccination for Immunoglobulin and FcγR.** (A, B) Scatter plots show subject-specific (line color) decline in immunoglobulin response and FcγR binding specific to WT Spike subdomains. Log-linear mixed-effect models with subject-specific random intercepts and slopes estimated trend-lines and 95% confidence intervals using data from subjects following the second BNT162b2 dose (dark-violet), second CoronaVac dose (light-blue), Hospitalized individuals (dark-purple), or Outpatient (light-pink). Horizontal grey lines indicate the innate Spike reactivity in Naïve (no-exposure) samples. Color legend shown at bottom for each panel. (C) Regression intercepts and slopes, indicating initial response and decay rate, are plotted with 95% confidence intervals for by each Spike subdomain. Decay and response parameters across variants (shapes) are stratified by infection/vaccination type (color and shape). Shaded out regions indicate a response < the 97.5<sup>th</sup> percentile of the naïve response. Y-axis units are MFI fold difference respect to the Naïve group.


**A****B****C**



**Supplemental FigS2. Spike-specific MFI decay across VOC over time post-infection or vaccination for Immunoglobulin and FcR.** (A, B) Scatter plots show subject-specific (line color) decline in immunoglobulin response and FcR binding specific to various VOC Spikes. Log-linear mixed-effect models with subject-specific random intercepts and slopes estimated trend-lines and 95% confidence intervals using data from subjects following the second BNT162b2 (dark-violet), dose, second CoronaVac dose (light-blue), Hospitalized individuals (dark-purple), or Outpatient (light-pink). Horizontal grey lines indicate the innate Spike reactivity in Naïve (no-exposure) samples. Color legend shown at bottom for each panel. (C) Regression intercepts and slopes, indicating initial response and decay rate, are plotted with 95% confidence intervals for by each Spike subdomain. Decay and response parameters across variants (shapes) are stratified by infection/vaccination type (color and shape). Shaded out regions indicate a response < the 97.5<sup>th</sup> percentile of the naïve response. Y-axis units are MFI fold difference respect to the Naïve group.


**A****B****C**

**Supplemental FigS3. RBD-specific MFI decay across VOC over time post-infection or vaccination for Immunoglobulin and FcR.** (A,B) Scatter plots show subject-specific (line color) decline in immunoglobulin response and FcR binding specific to various VOC RBDs. Log-linear mixed-effect models with subject-specific random intercepts and slopes estimated trend-lines and 95% confidence intervals using data from subjects following the second BNT162b2 (dark-violet), dose, second CoronaVac dose (light-blue), Hospitalized individuals (dark-purple), or Outpatient (light-pink). Horizontal grey lines indicate the innate spike reactivity in Naïve (no-exposure) samples. Color legend shown at bottom for each panel. (C) Regression intercepts and slopes, indicating initial response and decay rate, are plotted with 95% confidence intervals for by each Spike subdomain. Decay and response parameters across variants (shapes) are stratified by infection/vaccination type (color and shape). Shaded out regions indicate a response < the 97.5<sup>th</sup> percentile of the naïve response. Y-axis units are MFI fold difference respect to the Naïve group.




**Supplemental FigS4. Time to decay calculated from the log-linear regression models.** Point-ranges display the predicted decay periods over which each inoculation- or infection-induced initial response to corresponding naïve (no-exposure) response; the range corresponds to the time predicted for each model to reach the 97.5<sup>th</sup>, 50<sup>th</sup>, and 2.5<sup>th</sup> percentile of the naïve response distribution s.t.  $\text{Time} = (\text{Naïve}_{97.5^{\text{th}}, 50^{\text{th}}, 2.5^{\text{th}}} - \text{Decay}) / \text{Initial}$ . Color legend for group is shown on the right.






**Supplemental FigS6. Hybrid boosting expands binding breadth for both outpatient and hospitalized recoverees.** Point-ranges indicating the lowest response observed post-infection (circle/square) and the increase in response observed post-vaccination (line height) where response is  $\log_{10}(\text{MFI}/\text{MFI}_{\text{naive}})$ . Plots are stratified by assay, antigen, and VOC and colored by infection and vaccination type. Point-ranges are transparent if a multiple test corrected paired t-test on response is not significant ( $\text{FDR} > 0.1$ ). An opaque diamond is added above each point-range if the waned response is less than naïve, the boosted response is greater than naïve, and the multiple test corrected paired t-test is significant. Color legend for group is shown on the right. Y-axis units are MFI fold difference.



**Supplemental FigS7. Comparison of the peak response post-infection to the peak response following post-infection.** Violin plots comparing the immune response (MFI/MFI\_naive) to Omicron and WT Spike binding and function given either CoronaVac or Pfizer vaccination post-infection. (a) Violin plots compare the peak response post-infection to the peak response following post-infection vaccination. Q-values indicate the FDR corrected significance for each corresponding t-test.





**Supplemental FigS8. Comparison of waning with peak response following post-infection boosting.** Violin plots comparing the immune response (MFI/MFI\_naive) to Omicron and WT Spike binding and function given either CoronaVac or Pfizer vaccination post-infection. Violin plots compare waning with peak response following post-infection boosting. The infection-only boxplots (Out or Hosp) represent the fully waned response (response at the farthest timepoint following infection) while the paired post-infection vaccination boxplots represent peak immunity following vaccination. Q-values indicate the FDR corrected significance for each corresponding t-test.